Filing Flows › Comparisons › MAZE vs FENC
Maze Therapeutics vs Fennec Pharmaceuticals: MAZE and FENC compared
Maze Therapeutics is the larger company: $20.0M of revenue in its latest quarter (Q1 2026) against $17.9M for Fennec Pharmaceuticals (Q2 2026). Fennec Pharmaceuticals is more profitable, with an operating margin of 9.7% against -132.8%.
Where the money goes: MAZE and FENC
Maze Therapeutics (MAZE) · Q1 2026
Maze Therapeutics, Q1 2026: revenue $20.0M, operating margin -132.8%, net loss $24.2M, operating cash flow −$39.1M. The chart follows the revenue to costs, profit and cash.
Fennec Pharmaceuticals (FENC) · Q2 2026
Fennec Pharmaceuticals, Q2 2026: revenue $17.9M (+85% year over year), operating margin 9.7%, net earnings $2.0M, operating cash flow $50K. The chart follows the revenue to costs, profit and cash.
| Maze Therapeutics (MAZE) | Fennec Pharmaceuticals (FENC) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $20.0M | $17.9M |
| Revenue growth, Y/Y | — | +85% |
| Operating margin | -132.8% | 9.7% |
| Net earnings | −$24.2M | $2.0M |
| Net margin | -121.0% | 11.0% |
| Operating cash flow | −$39.1M | $50K |
Where the revenue comes from
Fennec Pharmaceuticals
- PEDMARK product sales, net: $17.2M (96%)
- Other revenue: $710K (4%)
Questions
Which is bigger, Maze Therapeutics or Fennec Pharmaceuticals?
Maze Therapeutics is the larger company: $20.0M of revenue in its latest quarter (Q1 2026) against $17.9M for Fennec Pharmaceuticals (Q2 2026).
Is Maze Therapeutics or Fennec Pharmaceuticals growing faster?
Fennec Pharmaceuticals is more profitable, with an operating margin of 9.7% against -132.8%.
More: Maze Therapeutics earnings · how Maze Therapeutics makes money · Fennec Pharmaceuticals earnings · how Fennec Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 12, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.